Gold prices tick higher on fresh U.S. tariff threats, Fed rate cut hopes
Globe Life (NYSE:GL) Executive Vice President and Chief Strategy Officer Michael Clay Majors sold 9,991 shares of common stock on August 1, 2025, for a total of $1,374,129. The shares were sold at prices ranging from $136.79 to $137.78, near the stock’s 52-week high of $144. The company’s shares have delivered an impressive 58.59% return over the past year, trading at a P/E ratio of 11.1. According to InvestingPro analysis, Globe Life currently appears fairly valued based on its Fair Value model.
On the same day, Majors also exercised options to acquire 10,000 shares of Globe Life common stock at a price of $100.74, for a total value of $1,007,400. InvestingPro data shows management has been actively buying back shares, demonstrating confidence in the company’s future. Discover 8 more exclusive InvestingPro Tips and access the comprehensive Pro Research Report for deeper insights into Globe Life’s financial health and growth prospects.
In other recent news, Globe Life has seen a series of significant developments that are likely to impact investor sentiment. The company recently received favorable news as the U.S. Attorney’s Office for the Western District of Pennsylvania and the Department of Justice concluded their investigations into Globe Life’s sales practices without any enforcement actions. This resolution has removed substantial regulatory uncertainty for the company. In light of these developments, several financial firms have adjusted their outlook on Globe Life. Morgan Stanley (NYSE:MS) upgraded Globe Life’s stock rating from Equalweight to Overweight, setting a new price target of $166.00, citing the closure of the investigations as a key factor. Similarly, TD Cowen reaffirmed its Buy rating with a $182.00 price target. Meanwhile, BMO Capital raised its price target to $149.00, maintaining a Market Perform rating, reflecting optimism about the company’s free cash flow and price-to-earnings metrics. Keefe, Bruyette & Woods also increased their price target to $160.00 while maintaining an Outperform rating. These recent developments highlight a positive shift in the company’s regulatory landscape and analyst sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.